Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 10:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lexiscan Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects

NCT01918995
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Regadenoson, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2013 · Synced Sep 6, 2026, 10:21 AM EDT
Withdrawn Phase 2 Interventional

Phase Analysis and Obstructive CAD on Rubidium PET

NCT01840696
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Regadenoson
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Sep 6, 2026, 10:21 AM EDT
Terminated Phase 4 Interventional Results available

Study With Aminophylline to Attenuate of the Side Effects of Regadenoson

NCT01250496
View directory record Official record
Conditions
Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 12, 2023 · Synced Sep 6, 2026, 10:21 AM EDT
Recruiting Phase 2 Interventional

Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT07761910
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cardiotoxicity, Locally Advanced Non-Small Cell Lung Cancer, Radiation Therapy
Interventions
PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz
Diagnostic Test · Device · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 6, 2026, 10:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System

NCT03331380
View directory record Official record
Conditions
CAD
Interventions
MRI scan - obj 1, MRI scans - obj 2, MRI scans - obj 3, MRI scans - obj 4
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
2,950 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 6, 2026, 10:21 AM EDT
Completed Phase 4 Interventional Results available

Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson

NCT01779869
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Regadenoson
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Sep 6, 2026, 10:21 AM EDT
Not listed No phase listed Observational

Evaluation of Myocardial Ischemia Using Standard Single Photon Emission Computed Tomography (SPECT) With Regadenoson and Simultaneous Cardiac Echocardiography

NCT01150578
View directory record Official record
Conditions
Myocardial Ischemia
Interventions
No intervention
Drug
Lead sponsor
Aiden Abidov
Other
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 6, 2026, 10:21 AM EDT
Not listed Phase 4 Interventional

Diagnostic Study of Rapid Regadenoson Stress Cardiovascular Magnetic Resonance (CMR) to Detect Coronary Artery Disease

NCT01446094
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
regadenoson
Drug
Lead sponsor
Dipan Shah
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Sep 6, 2026, 10:21 AM EDT
Completed No phase listed Observational

Assessment of Global Myocardial Perfusion Reserve Using Coronary Sinus Flow Measurements

NCT02697877
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Regadenoson
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Sep 6, 2026, 10:21 AM EDT
Completed Not applicable Interventional Results available

Stress CT Perfusion in Patients With Chest Pain

NCT01969916
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Regadenoson
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 6, 2026, 10:21 AM EDT
Completed Phase 4 Interventional Results available

Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction

NCT02597543
View directory record Official record
Conditions
Heart Transplant, Acute Graft Rejection, Chronic Graft Rejection
Interventions
Regadenoson, Gadolinium, Cardiac MRI
Drug · Procedure
Lead sponsor
Paul Kim
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Sep 6, 2026, 10:21 AM EDT
Not listed No phase listed Observational

Impact of Coronary Artery Stenting on Quantitative Myocardial Blood Flow and Health Status

NCT04475094
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Rubidium-82, Seattle Angina Questionnaire-7, Rose Dyspnea Scale
Drug · Behavioral
Lead sponsor
Cardiovascular Imaging Technologies
Industry
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Sep 6, 2026, 10:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Contrast- Enhanced Whole-Heart Coronary MRA at 3.0T (Tesla)

NCT02092428
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Image Quality, Diagnostic Accuracy
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Sep 6, 2026, 10:21 AM EDT
Completed Phase 3 Interventional Results available

An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)

NCT03354273
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
PET MPI, SPECT MPI, Pharmacological stress agents
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Sep 6, 2026, 10:21 AM EDT
Active, not recruiting No phase listed Observational

Improvement Assessment of Coronary Flow Dysfunction Using Fundamental Fluid Dynamics

NCT01719016
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Cardiac PET, Coronary catheterization
Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 100 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 6, 2026, 10:21 AM EDT
Completed No phase listed Observational

Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT

NCT03170817
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Cardiac Perfusion Rest/Stress Digital PET/CT, N-13 ammonia, Regadenoson
Diagnostic Test · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Sep 6, 2026, 10:21 AM EDT
Completed Not applicable Interventional

Reducing Radioisotope Dose: the Half-Dose CZT Study

NCT01518777
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Half-dose isotope for NuclearStressTest
Other
Lead sponsor
S.M.Chang, MD
Other
Eligibility
18 Years to 90 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 6, 2026, 10:21 AM EDT
Completed Phase 2 Interventional Results available

Use of Lexiscan for Myocardial Stress Perfusion Computed Tomography With a 3rd Generation Dual Source CT System

NCT03103061
View directory record Official record
Conditions
Cardiovascular Diseases, Coronary Artery Disease
Interventions
Lexiscan
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Sep 6, 2026, 10:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Stress Testing and Cardiac Magnetic Resonance

NCT00871260
View directory record Official record
Conditions
Coronary Disease
Interventions
regadenoson
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Sep 6, 2026, 10:21 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy

NCT06814587
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Bypass Graft (CABG)
Interventions
Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI), [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), SPECT MPI (Single Photon Emission Computed Tomography Myocardial Perfusion Imaging)
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 6, 2026, 10:21 AM EDT
Completed Early Phase 1 Interventional

Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson

NCT00881218
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Regadenoson
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 9, 2012 · Synced Sep 6, 2026, 10:21 AM EDT
Completed Phase 4 Interventional Results available

Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking

NCT02130453
View directory record Official record
Conditions
Ischemia
Interventions
Regadenoson
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 6, 2026, 10:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress

NCT01370265
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Regadenoson, Adenosine, N-13 ammonia
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 6, 2026, 10:21 AM EDT
Completed Phase 3 Interventional

ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)

NCT00208312
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Regadenoson, Adenosine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2009 · Synced Sep 6, 2026, 10:21 AM EDT